Diabetes could cost U.S. $3 trillion over decade (Morning Read)

UnitedHealth Group Inc., one of the nation's largest health insurers, predicts that a majority of Americans could have diabetes or pre-diabetes by 2020, at a cost of $3.35 trillion to the health care system over the next 10 years, reports the Minneapolis/St. Paul Business Journal.

Highlights of the important and interesting in the world of healthcare:

What cost diabetes? UnitedHealth Group Inc., one of the nation’s largest health insurers, predicts that a majority of Americans could have diabetes or pre-diabetes by 2020, at a cost of $3.35 trillion to the health care system over the next 10 years, reports the Minneapolis/St. Paul Business Journal.

Employers draw health reform line. What would happen if the rank and file of America’s employers, financially overwhelmed by the burden associated with sponsoring health coverage, suddenly opted out? Kaiser Health News asks.

Dr. Reddy’s buys U.S. penicillin plant. GlaxoSmithKline will sell a penicillin manufacturing facility in Bristol, Tennessee, to Dr. Reddy’s Laboratories, one of India’s largest drug makers, according to the News & Observer.

Zogenix shares slide after IPO. Shares of San Diego-based Zogenix (NASDAQ: ZGNX) slid to $3.98 a share in the first day of trading Tuesday after the drug-and-device startup substantially revised the terms of its initial public offering, raising less than anticipated, according to Xconomy San Diego.

GM stole the IPO limelight from biotechs. Both Zogenix and Anacor Pharmaceuticals failed to price last week while automaker General Motors stole the headlines with its $20 billion IPO, according to the Burrill Report.

But another IPO is cooking in North Carolina. Meanwhile, Tranzyme, a small Durham, North Carolina, company developing experimental treatments for gastrointestinal diseases, is planning to raise as much as $75 million in an initial public offering of stock, the N&A reports.

Shares0
Shares0